Entact Bio

📍 Watertown, United States👥 21 employees💰 Last funded Jun 2026
Biotechnology Research🌐 entactbio.com
Website LinkedIn
Entact Bio is developing a novel class of precision medicines that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitylase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has built its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs leverage the natural ability of DUBs to regulate and enhance protein function. By harnessing the power of DUBs, Entact is expanding the universe of treatable diseases and creating new options for patients who are underserved by current therapeutic modalities.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2021–2026 · investors recorded per year
2021220261
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Entact Bio?
Entact Bio has 3 investors on record on gritt.io.
When did Entact Bio last raise funding?
The most recent investment in Entact Bio recorded on gritt.io was in June 2026.
What industry is Entact Bio in?
Entact Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Entact Bio based?
Entact Bio is headquartered in Watertown, United States.